Profile data is unavailable for this security.
About the company
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
- Revenue in USD (TTM)5.75bn
- Net income in USD1.45bn
- Incorporated1999
- Employees19.80k
- LocationEdwards Lifesciences CorpOne Edwards WayIRVINE 92614United StatesUSA
- Phone+1 (949) 250-2500
- Fax+1 (302) 655-5049
- Websitehttps://www.edwards.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Illumina Inc | 4.43bn | -3.04bn | 20.74bn | 10.59k | -- | 14.42 | -- | 4.68 | -19.18 | -19.18 | 27.94 | 9.03 | 0.4961 | 2.86 | 6.26 | 418,224.80 | -34.09 | -6.20 | -45.61 | -7.28 | 62.00 | 66.39 | -68.71 | -15.48 | 0.8596 | 14.07 | 0.6087 | -- | -1.75 | 6.21 | 73.64 | -- | -7.91 | -- |
| West Pharmaceutical Services Inc. | 2.88bn | 524.90m | 21.46bn | 10.60k | 42.04 | 8.34 | 32.76 | 7.46 | 7.04 | 7.04 | 38.62 | 35.49 | 0.8037 | 4.26 | 5.68 | 271,405.70 | 14.22 | 15.61 | 16.93 | 18.65 | 35.69 | 38.06 | 17.70 | 18.47 | 1.68 | -- | 0.0751 | 10.69 | 2.18 | 11.43 | 2.28 | 23.76 | 28.16 | 6.20 |
| Zimmer Biomet Holdings Inc | 7.52bn | 997.10m | 21.64bn | 18.00k | 22.14 | 1.71 | 11.02 | 2.88 | 4.80 | 4.80 | 36.22 | 62.18 | 0.3515 | 0.9141 | 5.40 | 418,050.00 | 4.66 | 2.21 | 5.40 | 2.52 | 71.78 | 71.25 | 13.27 | 7.28 | 0.629 | 7.51 | 0.314 | 38.90 | 6.55 | -1.40 | 252.86 | -- | 9.44 | 0.00 |
| Cooper Companies Inc | 3.80bn | 359.30m | 21.87bn | 15.00k | 61.16 | 2.76 | 29.72 | 5.75 | 1.80 | 1.80 | 19.02 | 39.80 | 0.3196 | 1.70 | 5.56 | 253,606.70 | 3.02 | 10.06 | 3.29 | 11.34 | 66.36 | 65.54 | 9.45 | 29.00 | 1.18 | 5.46 | 0.2493 | 0.3469 | 8.61 | 7.24 | -23.74 | -3.66 | 15.18 | 31.95 |
| Steris PLC | 5.13bn | 567.70m | 23.83bn | 18.18k | 42.24 | 3.76 | 21.48 | 4.64 | 5.72 | 4.03 | 51.73 | 64.32 | 0.4914 | 3.98 | 5.77 | 282,395.10 | 5.45 | 5.19 | 5.95 | 5.68 | 43.19 | 43.64 | 11.09 | 10.97 | 1.49 | 7.03 | 0.2666 | 36.56 | 13.28 | 13.06 | -1.07 | 12.67 | 13.69 | 8.83 |
| DexCom Inc | 3.93bn | 666.90m | 27.63bn | 9.60k | 43.28 | 11.35 | 31.67 | 7.02 | 1.59 | 1.59 | 9.38 | 6.08 | 0.5778 | 2.92 | 4.64 | 409,875.00 | 9.79 | 8.30 | 13.57 | 10.50 | 63.16 | 65.90 | 16.95 | 14.14 | 2.48 | -- | 0.5063 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
| Mettler-Toledo International Inc | 3.75bn | 785.75m | 29.36bn | 16.00k | 38.07 | -- | 32.33 | 7.83 | 36.34 | 36.34 | 173.40 | -7.20 | 1.13 | 4.01 | 5.85 | 234,384.60 | 23.74 | 23.32 | 36.29 | 34.02 | 59.33 | 58.58 | 20.95 | 20.51 | 0.6337 | 13.58 | 1.08 | 0.00 | -3.35 | 5.23 | -9.60 | 8.85 | -5.90 | -- |
| Veeva Systems Inc | 2.57bn | 615.26m | 34.78bn | 7.17k | 55.73 | 6.70 | 53.37 | 13.52 | 3.85 | 3.85 | 15.69 | 32.04 | 0.4453 | -- | 6.27 | 358,846.80 | 10.65 | 11.97 | 12.97 | 15.36 | 73.35 | 72.00 | 23.91 | 23.74 | -- | -- | 0.00 | 0.00 | 9.68 | 22.35 | 7.79 | 18.00 | 21.68 | -- |
| Resmed Inc | 4.69bn | 1.02bn | 36.86bn | 9.98k | 36.25 | 7.58 | 30.77 | 7.87 | 6.92 | 6.92 | 31.76 | 33.11 | 0.6878 | 2.23 | 5.81 | 469,468.60 | 14.99 | 14.24 | 17.08 | 16.53 | 56.67 | 56.85 | 21.79 | 20.35 | 1.69 | 27.20 | 0.1269 | 32.62 | 10.95 | 12.44 | 13.75 | 19.98 | 8.23 | 5.34 |
| GE HealthCare Technologies Inc | 19.52bn | 1.58bn | 39.63bn | 51.00k | 25.12 | 5.08 | 17.86 | 2.03 | 3.45 | 3.45 | 42.57 | 17.08 | 0.6084 | 5.38 | 4.47 | 382,686.30 | 5.07 | -- | 6.79 | -- | 40.96 | -- | 8.33 | -- | 0.8155 | 5.38 | 0.5362 | -- | 6.60 | -- | -26.82 | -- | -- | -- |
| Agilent Technologies Inc | 6.50bn | 1.41bn | 39.75bn | 17.40k | 28.77 | 6.74 | 23.90 | 6.12 | 4.81 | 4.81 | 22.14 | 20.53 | 0.5996 | 2.87 | 5.06 | 358,950.30 | 13.04 | 11.00 | 16.13 | 13.25 | 54.75 | 53.29 | 21.75 | 18.01 | 1.37 | 55.86 | 0.3319 | 21.46 | -0.219 | 6.82 | -1.12 | 7.39 | 10.98 | 8.86 |
| Edwards Lifesciences Corp | 5.75bn | 1.45bn | 40.50bn | 19.80k | 28.11 | 5.44 | 25.53 | 7.05 | 2.39 | 2.43 | 9.48 | 12.35 | 0.6018 | 1.29 | 7.50 | 290,292.90 | 15.14 | 16.63 | 17.44 | 19.12 | 77.58 | 76.71 | 25.17 | 24.84 | 2.87 | -- | 0.0737 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
| IDEXX Laboratories, Inc. | 3.78bn | 845.63m | 42.16bn | 11.00k | 50.78 | 26.74 | 43.63 | 11.14 | 10.09 | 10.09 | 45.15 | 19.16 | 1.20 | 3.87 | 6.85 | 344,072.80 | 26.91 | 28.00 | 39.47 | 43.49 | 60.41 | 58.74 | 22.34 | 21.35 | 1.03 | 51.05 | 0.3742 | 0.00 | 8.72 | 10.59 | 24.44 | 17.39 | 1.68 | -- |
| Cencora Inc | 283.83bn | 1.86bn | 46.21bn | 42.00k | 25.46 | 49.94 | 15.49 | 0.1628 | 9.21 | 9.21 | 1,407.82 | 4.70 | 4.44 | 15.60 | 11.97 | 6,757,877.00 | 2.91 | 0.9542 | 13.38 | 3.95 | 3.37 | 3.14 | 0.6556 | 0.2178 | 0.5476 | 14.76 | 0.8169 | 76.85 | 9.89 | 9.32 | 2.74 | 10.79 | 6.38 | 5.00 |
Data as of Sep 19 2024. Currency figures normalised to Edwards Lifesciences Corp's reporting currency: US Dollar USD
33.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 50.96m | 8.46% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 31.76m | 5.27% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 26.01m | 4.32% |
| AllianceBernstein LPas of 30 Jun 2024 | 20.34m | 3.38% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 15.71m | 2.61% |
| Brown Advisory LLCas of 30 Jun 2024 | 13.80m | 2.29% |
| Geode Capital Management LLCas of 30 Jun 2024 | 13.24m | 2.20% |
| Walter Scott & Partners Ltd.as of 30 Jun 2024 | 12.81m | 2.13% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 8.54m | 1.42% |
| Fisher Asset Management LLCas of 30 Jun 2024 | 8.27m | 1.37% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
